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Abstract
Importance—A gold standard objective measure of nasal airway obstruction (NAO) does not
currently exist, so patient-reported measures are commonly used, particularly the Nasal
Obstruction Symptom Evaluation (NOSE) and the visual analog scale (VAS). However, questions
remain regarding how best to utilize these instruments.
Objectives—The goal of this study is to systematically review studies on NOSE and VAS scores
in NAO patients and compile and standardize the data to (1) define symptomatic and normative
values for (a) pre and post-surgical NAO patients, (b) asymptomatic individuals, and (c) the
general population, (2) determine if post-surgery scores are comparable to asymptomatic scores,
and (3) determine if there is a clinically useful pre-operative and post-operative score change.
Evidence Review—A systematic review of the literature was performed through PubMed for
studies assessing NOSE and VAS scores in patients with chronic NAO. Strict inclusion criteria
were applied to focus on anatomic obstruction only. For statistical analysis, the patients were
divided into asymptomatic, pre- and post-surgery NAO, and the general population.
Findings—The average NOSE and VAS scores for a patient with NAO were 65 ± 22 and 6.9 ±
2.3 respectively. The average post-surgery NOSE score was 23 ± 20 and VAS score was 2.1 ± 2.2.
The average asymptomatic individual NOSE score was 15 ± 17, and VAS score was 2.1 ± 1.6.
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The average NOSE and VAS scores for the general population were 42 ± 27 and 4.6 ± 2.6
respectively. The average pre- to post-surgical change was > 40 for NOSE and > 4 for VAS.
Conclusions and Relevance—We have shown that normative and abnormal value ranges for
NOSE and VAS can be established for clinical use. Given the consistency of both scales, we
conclude that these measures should be used as a clinically meaningful measure of successful
surgical outcomes.
Introduction
Assessing success of surgery for nasal airway obstruction (NAO) can be a challenge. The
clinical diagnosis of NAO is based on the patient’s subjective feeling, exam findings, and
the surgeon’s assessment. Treatment is focused on the anatomic source of obstruction as
determined by the surgeon, but the ultimate judge of a successful treatment is the patient’s
reported relief from the sense of obstruction. Since objective evaluation of nasal obstruction
by acoustic rhinometry, rhinomanometry, and other methods frequently does not correlate
strongly with patients’ subjective feelings of patency,1 physicians and researchers have
increasingly focused on patient-reported outcome measures to determine treatment
efficacy.2
Health-related quality of life (QOL) measures have become important in all fields of
medicine.3 These scales are patient-reported, validated questionnaires that, ideally, reflect
the severity of a disease in how it affects or impairs a patient’s life. If the validation process
is well-performed and targeted, the QOL instrument is thought to be “disease specific.”
Several QOL measures have been used to assess the burden of NAO over the years.3
However, the Nasal Obstruction Symptom Evaluation (NOSE) has emerged as a key and
frequently used QOL instrument specific to NAO in the surgical patient.4
The NOSE scale has been validated as a QOL instrument for septoplasty and functional
rhinoplasty.4 It asks patients to rate on a 0–4 scale, over the past month, their feelings on
five separate questions such as nasal congestion or ability to get air through the nose during
exercise. The total score is then multiplied by 5 for a maximum score of 100, with 0 being
asymptomatic and 100 being the worst-case scenario.
Another well validated and accepted patient-reported measure is the visual analog scale
(VAS). This simple numerical scale is a means of translating a subjective feeling into a
number; and in the setting of NAO, VAS can give real-time, immediate subjective feedback
on the magnitude of obstruction. The most common VAS used for NAO asks the patient to
rate their sensation of airflow on a scale from 0 to 10 with 0 being completely clear and 10
being completely obstructed. Both the NOSE and VAS scales have been used extensively to
assess post-surgical outcomes in NAO patients. Furthermore, both scales have also been
used in scenarios to assess NAO in random population samples and in patients with no
history of NAO.
The goal of this study was to use a systematic review of the literature to find studies that
have used either the NOSE or VAS scores in surgically-treated NAO patients and to compile
and standardize the data to (1) define symptomatic and normative values for (a) pre and
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post-surgical NAO patients, (b) those with no NAO complaint, and (c) the general
population, (2) determine if post-surgery scores are comparable to those reported by
asymptomatic individuals, and (3) determine if there is a clinically useful quantifiable
difference between pre-operative and post-operative scores in NAO patients.
Methods
Article Selection Process
A multi-step search of the web-based PubMed database from the National Library of
Medicine was performed using the search terms summarized in Table 1, with limits set to
include articles published up to December 2012. Abstracts and full articles were reviewed.
Since the objective of this review was to assess the effect of surgery in NAO patients, only
studies reporting NOSE and VAS scores for NAO patients, asymptomatic individuals, or the
general population were included for further review. Studies on patients with nasal
congestion due to other illnesses (e.g., common cold, flu, allergies, recent trauma, or facial
nerve paralysis) were excluded. Similarly, studies on non-surgical treatments for nasal
obstruction (i.e., pharmacological intervention) were not included (Figure 1).
Subsequently, articles were excluded when the following essential data were not reported:
(1) surgical treatment, (2) statistical significance between pre- and post-surgery differences,
and (3) actual NOSE and VAS scores. Articles were also excluded if (1) non-standard
NOSE survey was employed, (2) VAS score could not be re-scaled to a standard 0 to 10
scale, and (3) insufficient information was given to categorize the cohort as asymptomatic or
NAO patients.
Data Extraction
Once the 31 articles that satisfied inclusion criteria were identified (Figure 1), they were
separated into those with NOSE scores and those with VAS scores. Data extracted from
each article included: study design, interventions performed, NOSE/VAS scores, statistical
analysis, length of follow-up, and inclusion/exclusion criteria.
The data in each article were then divided into three groups: 1) Patients treated surgically for
nasal airway obstruction, 2) asymptomatic individuals, and 3) general population. This
“general population” group consisted of patients that were not seen specifically for a
rhinologic complaint (e.g., all patients visiting a physician clinic), and may include patients
with and without NAO. This group contrasts to the group of asymptomatic individuals in the
sense that the latter was evaluated by a physician and deemed to have no history of nasal
obstruction. If an individual article included several distinct groups with separate data sets,
these groupings were used separately as appropriate.
There was a wide variation amongst the studies in scaling the VAS – e.g. 0 to 10, 0 to 100,
-6 to 6, or 0 to 3. Thus, for the sake of comparison and standardization, all VAS scores were
numerically rescaled and standardized to a 0 to 10 scale, with 0 indicating a “clear nose” and
10 indicating “complete obstruction.”
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For each of the three groups, weighted-average NOSE and VAS scores were computed
using the sample size of each designated study as the weight. Weighted average standard
deviations were also calculated for each group using the standard deviations from each study
and again using the sample size of each study as the weight. Not all studies reported a
standard deviation, so only those with a reported number were used in the calculation. These
mean standard deviations are reported in this text as X ± Y, with X being the mean score and
Y being the mean standard deviation.
Results
Literature review
Our search generated a total of 533 citations, and identified a total of 183 potentially
relevant articles (Figure 1). Of these citations, 65 articles merited full text review. Based on
the above-listed inclusion criteria, a total of 31 articles were included in the analysis. Sixteen
articles included only NOSE scores, 11 included only VAS scores, and 4 included both. The
majority of articles assessed pre-surgery vs. post-surgery scores, with surgical techniques
ranging from radiofrequency turbinate ablation to open septorhinoplasty. Post-surgery
follow-up ranged from 1 month to more than 3 years, with the majority of articles following
up at 2 months or more. Patient age was typically > 18 years with the exception of two
articles which included one 16-year-old patient and one 14-year-old patient.
Despite the diversity of interventions and follow-up duration, all articles that assessed pre-
surgery vs. post-surgery scores found statistically significant improvement after treatment
based on a p-value ≤ 0.05 (Tables 3 and 5).
Several articles included the use of various objective methods of assessing NAO including
acoustic rhinometry and rhinomanometry to compare with the subjective scores, but their
correlations were inconsistent and beyond the scope of this review. Multiple articles used
alternative subjective assessments concurrent with either VAS or NOSE scores, but these
were also outside the scope of this review.
NOSE scale
The 20 articles with NOSE scores included 17 subject groups that underwent surgical
treatments and 2 more subject groups that had pre-operative assessment but no post-
operative assessment (Table 3). There were 7 non-surgical subject groups either fitting
general population or no NAO (Table 2). NOSE scores were all obtained with the standard
NOSE questionnaire.
The 19 pre-treatment subject groups had a total n = 725 patients, and the 17 post-treatment
groups had a total n = 643 patients. The NOSE scores for individual studies are listed in
tables 2 and 3. All treatment groups showed statistically significant difference between pre-
surgery and post-surgery scores. The weighted average NOSE score was 65 ± 22 pre-
surgery, decreasing to 23 ± 20 post-surgery, with a mean drop of 42 points (Table 6).
Of the 7 subject groups of non-surgical patients, 5 included NOSE scores for asymptomatic
individuals with no NAO (n = 163) and 2 included NOSE scores for a general population (n
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= 382). The weighted average NOSE score was 15 ± 17 for asymptomatic individuals and
42 ± 27 for the general population (Table 6).
VAS scores
The 15 articles with VAS scores included 10 subject groups that underwent surgical
treatments, and 9 subject groups with no treatment. It should be noted that there were several
different VAS scales used, but the majority using a variation of either 0–10 or 0–100, with 0
being a clear nose and 10 or 100 being complete obstruction. All were adjusted to 0–10 prior
to any data analysis. It should also be noted that all of the included studies used bilateral, not
unilateral nasal patency when assessing VAS.
The 10 subject groups with pre-surgery and post- surgery VAS had a total n = 265, and all
but one of the groups showed a statistically significant difference between pre-treatment and
post-treatment scores. The VAS scores for individual studies are listed in tables 4 and 5. The
weighted pre-treatment mean VAS was 6.7 ± 2.3 and the post-treatment mean was 2.1 ± 2.2,
with a mean change of 4.6 (Table 6).
Of the 8 subject groups of untreated patients, 5 included VAS for asymptomatic individuals
with no nasal obstruction symptoms (n = 186), and 3 included VAS for the general
population (n = 3,063). The weighted average VAS for individuals with no NAO was 2.1 ±
1.6, and for the general population it was 4.6 ± 2.6 (Table 6).
Discussion
Surgery for NAO is among the most commonly performed in the field of otolaryngology,
yet reported failure rates can vary from 20 to 50 percent.5–8 Because of the lack of a gold
standard objective measure for nasal patency, patient-reported, disease-specific measures
have emerged as perhaps the most clinically meaningful assessment tools to quantify
treatment success. The importance of establishing normative and symptomatic ranges and
defining meaningful clinical numerical changes to the scores is paramount in measuring the
success of an intervention. By performing a systematic review and pooling and
standardizing the data, we have been able to demonstrate that normative and abnormal value
ranges can be established for meaningful clinical use.
The NOSE and VAS scores for NAO in the included studies showed a surprising amount of
consistency amongst the studies despite the diversity of patient populations, interventions,
and surgical techniques. This consistency, with tight groupings of scores in each category,
lends credibility to the category means listed in table 6 as a categorization for normative
values for NAO.
The average NOSE score for patients who sought NAO corrective surgery was 65, and no
individual study had an average value below 57 (Tables 3 and 6). Similarly, the average
VAS score for patients with NAO was 6.7, and the lowest individual study average was 5.2
(Tables 5 and 6). As expected, the average scores for populations with no history of NAO
(i.e. asymptomatic) were significantly lower, with a NOSE average of 15 and VAS average
of 2.1 (Table 6). No individual study’s NOSE score was higher than 18 for asymptomatic
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individuals, and only one of the VAS studies had an average score higher than 2.0 (Tables 2
and 4). There was no score overlap between obstructed and non-obstructed study
populations, showing a clear demarcation based on the patient-reported measures, thus
defining normative and symptomatic values.
As expected, the average scores for the general population fell into the range between the
average scores of NAO patients and asymptomatic individuals, with the full range of NAO
symptoms (none to severe) represented. This was true for both NOSE and VAS general
population averages, with scores of 42 and 4.6 respectively (Table 6).
In addition, we wanted to determine the mean NOSE and VAS scores for post-surgical NAO
patients. We suspected that post-operative scores might demonstrate a bias, or placebo
effect, with patients anticipating and reporting lower scores than a non-obstructed, untreated
patient. Interestingly, we found that post-operative patients reported the same average VAS
as asymptomatic individuals at 2.1 (Table 6). Similarly, the post-operative mean NOSE
score was close to the non-obstructed, untreated group, though the score was slightly higher
at 23 for post-operative patients, as compared to 15 for the asymptomatic individuals. The
similarity of post-surgical NAO scores and asymptomatic scores indicate that the goal of
surgery may realistically be to achieve “normal” breathing as perceived by the patient.
It is important to note that the scores reported in tables 2–6 are average scores, and that there
was a small percentage of patients in most studies who did not have post-surgical
improvement in NOSE and/or VAS scores. However, the majority of patients reported
significant improvement, as demonstrated by the statistical significance of pre- to post-
surgery differences.
The average pre- to post-surgery NOSE score change was 42 points, and the change in VAS
was 4.6. No individual study reported a pre- to post-surgery drop <30 for NOSE or <3.0 for
VAS (Tables 3 and 5). All but one of the included studies showed statistically significant
change from pre- to post-surgery scores. Thus, one clinically meaningful measure of
surgical success may be considered a change of ≥30 for NOSE and ≥3.0 for VAS. This
threshold of change does not necessarily mean that lesser post-operative changes are not
successful – the ultimate measure is patient specific – however, the results of this study
would suggest that a quantifiable target may potentially be set by the surgeon and patient in
terms of a successful outcome.
There are numerous potential implications and applications from the findings of this study.
Normative and symptomatic values may help stratify the severity of NAO – e.g. normal,
mild, moderate, and severe. This information can also be used to educate patients and give
realistic expectations for improvement of NAO symptoms following procedures. These
values may also help guide treatment. For example, a patient with a NOSE score of 60, with
enlarged inferior turbinates and a deviated septum could reasonably be expected to have a
score improvement of >30 with surgery. This numerical expectation of improvement can be
compared to alternatives to surgery such as a nasal steroid treatment.
There are some potential areas of inconsistency and weakness in this review. The timing of
initial patient-reported testing was not always clear, and the follow-up varied greatly,
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ranging from only one month to several years. There was also a large amount of variability
amongst the studies in how the VAS was scaled, with score ranges from -6 to 6, from 0 to 3,
0 to 10 and 0 to 100. Though these scores were converted and standardized into a uniform
scale before data analysis, a single standardized VAS scale would have been preferable as in
the case of the NOSE scores. For standardization, we recommend that future studies should
use a 0–10 scale with 0 being a clear nose and 10 being a completed obstructed nose.
Another possible weakness of this study is the possibility of reporting bias in the literature –
i.e. researchers may preferentially report good outcomes. In addition, the surgical procedures
reported in the studies were also widely variable, though this diversity of procedures speaks
to the individualized nature of surgery for NAO and the varying expertise and preferences of
the treating surgeon. Finally, the fact that we focused solely on surgical treatment for NAO
gives this study a specific niche, and makes our results less applicable to NAO that has non-
surgical causes (e.g., allergic rhinitis) and treatments (e.g., pharmacological treatment).
In conclusion, this review demonstrated that both NOSE and VAS scores are consistent and
reliable patient-reported scales when used for evaluation of NAO. We have shown that
normative and symptomatic value ranges can be established for meaningful clinical use.
Furthermore, we conclude that physicians, researchers, and other stakeholders may consider
using these patient-reported measures as a reliable and clinically meaningful measure of
successful surgical outcomes.
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Summary of literature review for nasal obstruction terms listed in table 1, including papers
published until December 2012.
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Table 1
Pubmed search terms and resulting citations.
Search term Number of papers
1. "NOSE score" 16
2. "nasal obstruction symptom evaluation" 41
3. "visual analog scale + nasal obstruction" 245
4. "visual analog scale + nasal patency" 61
5. "VAS + nasal obstruction" 144
6. "VAS + nasal patency" 26
Total 533
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Table 2
NOSE scores for cohorts with no treatment.
Asymptomatic individuals
Study Sample size and characteristics NOSE score
Stewart 20044 12 patients with non-rhinologic complaints 11 (NA)
Lindemann 20109
40 patients mean age 27 with no NAO 13 ± 14
40 patients mean age 70 with no NAO 18 ± 21
Yoo 201110 21 patients with no NAO 13 ± 16
Marro 201111 50 patients with no NAO 16 ± 18
General population
Study Sample size and characteristics NOSE score
Lam 200612 270 adults referred for polysomnogram 41 ± 25
Ishii 201113 112 patients visiting facial plastics department for any complaint 45 ± 32
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Table 4
VAS scores for cohorts with no treatment.
No nasal airway obstruction
Study Sample size and characteristics VAS scores*
Clarke 199227 50 patients with no history of NAO and normal exam 1.7 (NA)
Clarke 199528 20 patients with no history of nasal disease 4.5 (3.0–5.9)
Roithmann 199829 51 with no NAO 1.9 (NA)
Zhao 201130 44 healthy volunteers 2.0 (NA)
Yoo 201110 21 patients with no NAO complaint 1.2 ± 1.6
General population
Study Sample size and characteristics VAS scores*
Jones 198931 250 subjects chosen as random population sample 4.6 ± 0.7
Lam 200612 290 adults referred for PSG 3.8 ± 3.0
Kjaergaard 200832 2523 patients referred for sleep disorders or chronic nasal complaints 4.7 ± 2.7
*
VAS scores were rescaled to a 0–10 scale, with 0 being no obstruction and 10 being the most obstructed.
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Table 6
Average NOSE and VAS scores*
Compiled NOSE weighted means
Pre-treatment 65 ± 22
Post-treatment 23 ± 20
Pre-treatment to post-treatment change 42
Healthy 15 ± 17
General population 42 ± 27
Compiled VAS weighted means
Pre-treatment 6.7 ± 2.3
Post-treatment 2.1 ± 2.2
Pre-treatment to post-treatment change 4.6
Healthy 2.1 ± 1.6
General population 4.6 ± 2.6
*
Scores reported as X ± Y, with X being the weighted mean score and Y being the weighted mean standard deviation
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